Received Jun 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 1 | — | — |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 2 | — | — |
No additional AE; the patient's initial dose was administered on 11/29/2006 and his second was administered earlier than 6-months after the initial dose on 05/18/2007; This spontaneous report was received from a nurse and refers to a 19-year-old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 29-NOV-2006, the patient was vaccinated with the first dose of Hepatitis A Vaccine, Inactivated (VAQTA) and on 18-MAY-2007, the patient was vaccinated with the second dose of Hepatitis A Vaccine, Inactivated (VAQTA) (dose, anatomical location, route of administration, lot number and expiration date were not reported for both vaccines) for prophylaxis. The healthcare provider (HCP) wanted to know if it was safe or recommended to administer 2 doses of the pediatric formulation of Hepatitis A Vaccine, Inactivated (VAQTA) in lieu of the one adult dose formulation of Hepatitis A Vaccine, inactivated (VAQTA) because the office did not have an adult dose on hand. The HCP stated the patient needed a booster dose of Hepatitis A Vaccine, Inactivated (VAQTA) for pilot school because the patient's initial dose was administered on 29-NOV-2006 and his second was administered earlier than 6-months after the initial dose on 18-MAY-2007 (inappropriate schedule of product administration). It was unknown by the HCP if the patient had a titer drawn initiating the need of a third "booster" dose of Hepatitis A Vaccine, Inactivated (VAQTA) and the nurse was under the impression the booster was required as a standard protocol for the patient to go to pilot school, but the nurse stated the patient had not experienced any other adverse issues or side effects related to the prior administered doses. No additional adverse event (AE).